It’s illegal to advertise prescription drugs. Novo Nordisk, which makes Ozempic and Wegovy, has not named any drugs in its ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Just today, this drug became more widely available. Some product is now facing a recall following an apparent storage error.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

The stock of Hims & Hers Health Inc. (HIMS) fell more than 4% in after-hours trading after the telehealth company issued ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...